FDA Clears First Targeted Dermatomyositis Treatment From Roivant
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.
A medicine company called Roivant got official approval to sell a new medicine that helps people with a rare skin disease. This is a big deal because it shows the company can actually make something doctors will use, which is good news for the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.